News for Immuron Stock (IMRN)

Can the 800% Gain in Immuron Be Rationalized Very Easily?

24/7 Wall Street • 06/09/20

Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA

Market Watch • 06/09/20

Immuron's Stock Surges 300% On US Navy Contract

Benzinga • 06/09/20

US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea

GlobeNewsWire • 06/09/20

Immuron Board Relinquish Cash Payment of Fees

GlobeNewsWire • 04/28/20

Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%

GlobeNewsWire • 04/20/20

Resignation of CEO & Director and cost cutting amidst COVID-19

GlobeNewsWire • 03/25/20

Immuron Provides Update on First Half of FY20 Results

GlobeNewsWire • 03/03/20

Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak

GlobeNewsWire • 02/03/20

North American Travelan® sales up 98% in the first half of FY20

GlobeNewsWire • 01/28/20

Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea

GlobeNewsWire • 11/21/19

Immuron Receives AUD $0.53M R&D Tax Concession Refund

GlobeNewsWire • 11/04/19

Immuron North American Q1 Sales Up 111% YoY

GlobeNewsWire • 10/14/19

Immuron Receives $3.7M In Federal Dollars For Traveler's Diarrhea Preventative Therapy Project

Benzinga • 10/02/19

New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter

GlobeNewsWire • 10/02/19

U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea

GlobeNewsWire • 09/04/19

Immuron Rips Higher On Positive Preclinical Results For Travelan

Benzinga • 06/12/19